Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Ebert

Showing results (251-260 of 339) with videos related to

Pageof 34
Sort By:
Cancer Research|March 31, 2025
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative EffectNancy Klemm, Roman R Schimmer, Nils K Konrad, et al.
Blood|September 12, 2022
Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19Peter G Miller, Geoffrey G Fell, Brody H Foy, et al.
Blood|August 18, 2023
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancyPeter G Miller, Adam S Sperling, Christina Mayerhofer, et al.
European Heart Journal|November 12, 2023
Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmiasArt Schuermans, Caitlyn Vlasschaert, Victor Nauffal, et al.
Science Translational Medicine|April 13, 2018
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasmsOfir Wolach, Rob S Sellar, Kimberly Martinod, et al.
Blood Advances|July 21, 2019
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantationMax Jan, Matthew J Leventhal, Elizabeth A Morgan, et al.
Nature Cardiovascular Research|August 28, 2024
Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypesPhilipp J Rauch, Jayakrishnan Gopakumar, Alexander J Silver, et al.
Journal of the American Chemical Society|June 26, 2026
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II InhibitionJi Hyeon Kim, Caitlin E Mills, Zuzanna Kozicka, et al.
Science (New York, N.Y.)|August 10, 2019
A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignanciesSteffen Boettcher, Peter G Miller, Rohan Sharma, et al.
Cell|January 19, 2011
Densely interconnected transcriptional circuits control cell states in human hematopoiesisNoa Novershtern, Aravind Subramanian, Lee N Lawton, et al.
Pageof 34

Showing results (251-260 of 339) with videos related to

Sort By:
Pageof 34
Cancer Research|March 31, 2025
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wild-Type p53 to Exert the Dominant-Negative EffectNancy Klemm, Roman R Schimmer, Nils K Konrad, et al.
Blood|September 12, 2022
Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19Peter G Miller, Geoffrey G Fell, Brody H Foy, et al.
Blood|August 18, 2023
PPM1D modulates hematopoietic cell fitness and response to DNA damage and is a therapeutic target in myeloid malignancyPeter G Miller, Adam S Sperling, Christina Mayerhofer, et al.
European Heart Journal|November 12, 2023
Clonal haematopoiesis of indeterminate potential predicts incident cardiac arrhythmiasArt Schuermans, Caitlyn Vlasschaert, Victor Nauffal, et al.
Science Translational Medicine|April 13, 2018
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasmsOfir Wolach, Rob S Sellar, Kimberly Martinod, et al.
Blood Advances|July 21, 2019
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantationMax Jan, Matthew J Leventhal, Elizabeth A Morgan, et al.
Nature Cardiovascular Research|August 28, 2024
Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and concordant macrophage phenotypesPhilipp J Rauch, Jayakrishnan Gopakumar, Alexander J Silver, et al.
Journal of the American Chemical Society|June 26, 2026
A Type II CDK6 Degrader Enables Cellular Targeting beyond the Limits of Type II InhibitionJi Hyeon Kim, Caitlin E Mills, Zuzanna Kozicka, et al.
Science (New York, N.Y.)|August 10, 2019
A dominant-negative effect drives selection of <i>TP53</i> missense mutations in myeloid malignanciesSteffen Boettcher, Peter G Miller, Rohan Sharma, et al.
Cell|January 19, 2011
Densely interconnected transcriptional circuits control cell states in human hematopoiesisNoa Novershtern, Aravind Subramanian, Lee N Lawton, et al.
Pageof 34